Aristada Injection, Suspension, Extended Release
Product Images NDC 65757-403

Product Visual Gallery

This gallery contains 19 technical images submitted to the FDA as part of the official labeling for Aristada (NDC 65757-403). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Alkermes, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Ari01 0034 01

FDA Label Image

Ari01 0034 02

FDA Label Image

Ari01 0034 03

FDA Label Image

Ari01 0034 04

FDA Label Image

Ari01 0034 05

FDA Label Image

Ari01 0034 06

FDA Label Image

Ari01 0034 07

FDA Label Image

Ari01 0034 08

FDA Label Image

Ari01 0034 09

FDA Label Image

Ari01 0034 10

FDA Label Image

Ari01 0034 11

FDA Label Image

Ari01 0034 12

FDA Label Image

Ari01 0034 13

FDA Label Image

Ari01 0034 14

Not available. The provided text seems incomplete and contains several errors and non-English characters.*

FDA Label Image

Ari01 0034 15

The text provides a graph showing the change from baseline in the PANSS Total Score, with the treatment group indicated. However, the content is not well-organized and does not include a clear description.*

FDA Label Image

Ari01 0034 16

This is a description of a medication with the NDC code 65757-401-03 for extended-release injectable suspension. It must be administered by a healthcare professional into the deltoid or gluteal muscles, and the entire content of the syringe must be administered in a single dose. The medication contains 441 mg/1.6 mL to be injected monthly, and the accompanying full prescribing information should be consulted for dosing and administration instructions. The medication guide must be dispensed to the patient. The medication should be stored at room temperature, and away from children. The instructions should be read before use.*

FDA Label Image

Ari01 0034 17

This text appears to be a set of instructions and information regarding the administration of a medication called Aristada, specifically for intramuscular injection. It provides details about the dosage and storage of the medication, and advises that the medication should only be administered by a healthcare professional. Additionally, it directs the reader to see accompanying instructions and dispense a Medication Guide to the patient. There are also warnings to keep the medication out of reach of children and to read the complete instructions prior to use.*

FDA Label Image

Ari01 0034 18

FDA Label Image

Ari01 0034 19

This is a prescription drug instruction leaflet for the injectable medication "Aristada", which contains the drug aripiprazole lauroxil. Aristada is administered by healthcare professionals, and is a single-dose injection given every two months. It is to be injected in the gluteal muscles only, and must be administered in full. The text also includes storage instructions, safety precautions and prescription details in the form of an NDC code.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.